ArticleThe Journal of clinical investigation2000
HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death.
Article in The Journal of clinical investigation, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 91 citations in OpenAlex.
- Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2009Trial
- Immune Activation and HIV-Specific CD8(+) T Cells in Cerebrospinal Fluid of HIV Controllers and Noncontrollers.AIDS research and human retroviruses · 2016Article
- Human AdV-specific T cells: persisting in vitro functionality despite lethal irradiation.Bone marrow transplantation · 2014Article
- Enhanced anti-HIV efficacy of indinavir after inclusion in CD4-targeted lipid nanoparticles.Journal of acquired immune deficiency syndromes (1999) · 2012Article
- Design and characterization of novel peptide-coated lipid nanoparticles for targeting anti-HIV drug to CD4 expressing cells.The AAPS journal · 2012Article
- Distinct kinetics of Gag-specific CD4+ and CD8+ T cell responses during acute HIV-1 infection.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- Stem cell-based anti-HIV gene therapy.Virology · 2011Review
- Dynamic regulation of functionally distinct virus-specific T cells.Proceedings of the National Academy of Sciences of the United States of America · 2010Article
- Engineering antigen-specific T cells from genetically modified human hematopoietic stem cells in immunodeficient mice.PloS one · 2009Article
- NanoART, neuroAIDS and CNS drug delivery.Nanomedicine (London, England) · 2009Review
- Enhancement of human immunodeficiency virus (HIV)-specific CD8+ T cells in cerebrospinal fluid compared to those in blood among antiretroviral therapy-naive HIV-positive subjects.Journal of virology · 2008Article
- Soluble PD-1 rescues the proliferative response of simian immunodeficiency virus-specific CD4 and CD8 T cells during chronic infection.Immunology · 2008Article
- Failure of low-dose recombinant human IL-2 to support the survival of virus-specific CTL clones infused into severe combined immunodeficient foals: lack of correlation between in vitro activity and in vivo efficacy.Veterinary immunology and immunopathology · 2008Article
- Genetic therapies against HIV.Nature biotechnology · 2007Review
- Decreased CXCR3+ CD8 T cells in advanced human immunodeficiency virus infection suggest that a homing defect contributes to cytotoxic T-lymphocyte dysfunction.Journal of virology · 2007Article
- Brain CD8+ and cytotoxic T lymphocytes are associated with, and may be specific for, human immunodeficiency virus type 1 encephalitis in patients with acquired immunodeficiency syndrome.Journal of neurovirology · 2006Article
- How many human immunodeficiency virus type 1-infected target cells can a cytotoxic T-lymphocyte kill?Journal of virology · 2005Article
- Adoptive T cell therapy: Addressing challenges in cancer immunotherapy.Journal of translational medicine · 2005Article
- Article
- Article
Corrections and comments
- Retraction · 2010-09-01Falsification/Fabrication of Image · Investigation by ORI · Misconduct - Official Investigation(s) and/or Finding(s) · Upgrade/Update of Prior Notice(s) · · Findings of Misconduct for Scott Brodie; Expression of Concern DOI: 10.1172/JCI8707EX1; JME 06/26/2017
- Commented on by
- Commented on by
- Expression of concern
- Retracted
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
We have tracked the in vivo migration and have identified in vivo correlates of cytotoxic T-lymphocyte (CTL) activity in HIV-seropositive subjects infused with autologous gene-marked CD8(+) HIV-specific CTL. The number of circulating gene-marked CTL ranged from 1.6 to 3.5% shortly after infusion to less than 0.5% 2 weeks later. Gene-marked CTL were present in the lymph node at 4.5- to 11-fold excess and colocalized within parafollicular regions of the lymph node adjacent to cells expressing HIV tat fusion transcripts, a correlate of virus replication. The CTL clones expressed the CCR5 receptor and localized among HIV-infected cells expressing the ligands MIP-1alpha and MIP-1beta, CC-chemokines produced at sites of virus replication. Aggregates of apoptotic cells and cells expressing granzyme-B localized within these same sites. In contrast, lymph node sections from untreated HIV-seropositive subjects, all with significant viral burden (> 50,000 HIV RNA copies/mL plasma), showed no CC-chemokine expression and exhibited only sporadic and randomly distributed cells expressing granzymes and/or apoptotic cells. These studies show that the infused CTL specifically migrate to sites of HIV replication and retain their antigen-specific cytolytic potential. Moreover, these studies provide a methodology that will facilitate studies of both the magnitude and functional phenotype of Ag-specific CD8(+) T cells in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.